Publication: Therapeutic potential of pteridine derivatives: a comprehensive review
Authors
Carmona‐Martínez, Violeta ; Vera, María ; Guirado, Antonio ; García-Peñarrubia, Pilar ; Martínez-Esparza Alvargonzález, María Concepción ; Ruiz Alcaraz, Antonio José
item.page.secondaryauthor
item.page.director
Publisher
Wiley
publication.page.editor
publication.page.department
DOI
http://doi.org/10.1002/med.21529
item.page.type
info:eu-repo/semantics/article
Description
© 2018 Wiley Periodicals, Inc. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/. This document is the Acepted version of a Published Work that appeared in final form in Medicinal Research Reviews. To access the final edited and published work see
https://doi.org/ 10.1002/med.21529
Abstract
Pteridines are aromatic compounds formed by fused pyrazine and pyrimidine rings. Many living organisms synthesize pteridines, where they act as pigments, enzymatic cofactors, or immune system activation molecules. This variety of biological functions has motivated the
synthesis of a huge number of pteridine derivatives with the aim of studying their therapeutic potential. This review gathers the state‐of‐the‐art of pteridine derivatives, describing their biological activities and molecular targets. The antitumor activity of pteridine‐based compounds is one of
the most studied and advanced therapeutic potentials, for which several molecular targets have been identified. Nevertheless, pteridines are also considered as very promising therapeutics for the treatment of chronic inflammation‐related diseases. On the other hand, many pteridine
derivatives have been tested for antimicrobial activities but, although some of them resulted to be active in preliminary assays, a deeper research is needed in this area. Moreover, pteridines may be of use in the treatment of many other diseases, such as diabetes, osteoporosis, ischemia, or
neurodegeneration, among others. Thus, the diversity of the biological activities shown by these compounds highlights the promising therapeutic use of pteridine derivatives. Indeed, methotrexate, pralatrexate, and triamterene are Food and Drug Administration approved pteridines, while
many others are currently under study in clinical trials.
publication.page.subject
Citation
Medicinal Research Reviews. Mar 39(2): 461-516
item.page.embargo
Collections
Ir a Estadísticas
Este ítem está sujeto a una licencia Creative Commons. http://creativecommons.org/licenses/by-nc-nd/4.0/